Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
Background: Previous studies have suggested that patients with HER2-low breast cancers do not benefit from trastuzumab treatment although the reasons remain unclear. Methods: We investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel...
| Hlavní autoři: | , , , , , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
Springer Nature [academic journals on nature.com]
2024
|